Petros Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Petros Pharmaceuticals, Inc. (PTPI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $117.91 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $117.91K, a 58.64% increase year-over-year.
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $74.32K, a 341.49% increase year-over-year.
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $0.00.
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $304.63K, a 54.47% increase from fiscal 2024.
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $197.22K.
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.20M, a 6.96% increase from fiscal 2021.
- Petros Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $1.12M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $117.91K 10-Q · filed 2026-08-13 | |||||
| 2025-12-31 | $304.63K 10-K · filed 2026-04-15 | |||||
| 2025-06-30 | $74.32K 10-Q · filed 2026-08-13 | $154.36K 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $0.00 derived: sum of 2 quarters · filed 2026-04-15 | $16.83K derived: sum of 3 quarters · filed 2026-04-15 | $197.22K 10-K · filed 2026-04-15 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $16.83K derived: sum of 2 quarters · filed 2024-11-13 | $197.22K 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $16.83K 10-Q · filed 2024-08-14 | $197.22K 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $180.38K 10-Q · filed 2024-05-15 | |||||
| 2023-09-30 | $30.84K 10-Q · filed 2024-11-13 | $74.16K derived: sum of 2 quarters · filed 2024-11-13 | $204.49K 10-Q · filed 2024-11-13 | $433.34K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $43.32K 10-Q · filed 2024-08-14 | $173.65K 10-Q · filed 2024-08-14 | $402.50K derived: sum of 3 quarters · filed 2024-08-14 | $710.63K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $130.34K 10-Q · filed 2024-05-15 | $359.18K derived: sum of 2 quarters · filed 2024-05-15 | $667.32K derived: sum of 3 quarters · filed 2024-05-15 | $969.58K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $228.84K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $536.98K derived: sum of 2 quarters · filed 2023-11-15 | $839.25K derived: sum of 3 quarters · filed 2023-11-15 | $1.20M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $308.14K 10-Q · filed 2023-11-15 | $610.40K derived: sum of 2 quarters · filed 2023-11-15 | $966.23K 10-Q · filed 2023-11-15 | $1.09M derived: sum of 4 quarters · filed 2023-11-15 | ||
| 2022-06-30 | $302.26K 10-Q · filed 2023-08-14 | $658.09K 10-Q · filed 2023-08-14 | $784.57K derived: sum of 3 quarters · filed 2023-08-14 | $837.73K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $355.83K 10-Q · filed 2023-05-15 | $482.30K derived: sum of 2 quarters · filed 2023-05-15 | $535.47K derived: sum of 3 quarters · filed 2023-05-15 | $1.13M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $126.47K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $179.64K derived: sum of 2 quarters · filed 2023-03-31 | $770.14K derived: sum of 3 quarters · filed 2023-03-31 | $1.12M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $53.17K 10-Q/A · filed 2022-11-15 | $643.67K derived: sum of 2 quarters · filed 2022-11-15 | $990.88K 10-Q/A · filed 2022-11-15 | |||
| 2021-06-30 | $590.50K 10-Q · filed 2022-08-12 | $450.50K 10-Q · filed 2021-08-16 | $937.71K 10-Q · filed 2022-08-12 | $797.71K 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $347.21K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |